BACKGROUND: Proteasome inhibitors are anticancer compounds that disrupt the proteolytic activity of the proteasome and lead to tumor cell growth arrest and apoptosis. Bortezomib is a proteasome inhibitor that is currently approved for use in multiple myeloma (MM) and mantle-cell lymphoma. It induces apoptosis of chronic myeloid leukemia (CML) cells in vitro, but the activity of bortezomib in patients with imatinib-resistant CML is unknown. METHODS: We conducted a pilot trial to evaluate the activity of single-agent bortezomib in CML. Seven patients with imatinib-refractory CML were treated with bortezomib at a dose of 1.5 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. RESULTS: The median number of cycles received was 2. No patient had a hematologic or cytogenetic response. Three patients had a temporary decrease in basophil counts associated with therapy with bortezomib. Six patients experienced grade 3/4 nonhematologic toxicities. CONCLUSION: Bortezomib had minimal efficacy and considerable toxicity in patients with imatinib-refractory CML. Further studies should focus on alternative approaches to using proteasome inhibitors in the treatment of CML, such as in combination with tyrosine kinase inhibitors (TKIs) or as a strategy to eradicate leukemic stem cells.
BACKGROUND: Proteasome inhibitors are anticancer compounds that disrupt the proteolytic activity of the proteasome and lead to tumor cell growth arrest and apoptosis. Bortezomib is a proteasome inhibitor that is currently approved for use in multiple myeloma (MM) and mantle-cell lymphoma. It induces apoptosis of chronic myeloid leukemia (CML) cells in vitro, but the activity of bortezomib in patients with imatinib-resistant CML is unknown. METHODS: We conducted a pilot trial to evaluate the activity of single-agent bortezomib in CML. Seven patients with imatinib-refractory CML were treated with bortezomib at a dose of 1.5 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. RESULTS: The median number of cycles received was 2. No patient had a hematologic or cytogenetic response. Three patients had a temporary decrease in basophil counts associated with therapy with bortezomib. Six patients experienced grade 3/4 nonhematologic toxicities. CONCLUSION:Bortezomib had minimal efficacy and considerable toxicity in patients with imatinib-refractory CML. Further studies should focus on alternative approaches to using proteasome inhibitors in the treatment of CML, such as in combination with tyrosine kinase inhibitors (TKIs) or as a strategy to eradicate leukemic stem cells.
Authors: Z Dai; R C Quackenbush; K D Courtney; M Grove; D Cortez; G W Reuther; A M Pendergast Journal: Genes Dev Date: 1998-05-15 Impact factor: 11.361
Authors: Enrique J Andreu; Elisa Lledó; Enric Poch; Carmen Ivorra; M Pilar Albero; José Angel Martínez-Climent; Cristina Montiel-Duarte; José Rifón; Javier Pérez-Calvo; Cristina Arbona; Felipe Prósper; Ignacio Pérez-Roger Journal: Cancer Res Date: 2005-04-15 Impact factor: 12.701
Authors: M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe Journal: Science Date: 1995-08-04 Impact factor: 47.728
Authors: Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Denise Niewerth; Gertjan J L Kaspers; Gerrit Jansen; Johan van Meerloo; Sonja Zweegman; Gaye Jenkins; James A Whitlock; Stephen P Hunger; Xiaomin Lu; Todd A Alonzo; Peter M van de Ven; Terzah M Horton; Jacqueline Cloos Journal: J Hematol Oncol Date: 2016-09-06 Impact factor: 17.388
Authors: Alfonso E Bencomo-Alvarez; Andres J Rubio; Idaly M Olivas; Mayra A Gonzalez; Rebecca Ellwood; Carme Ripoll Fiol; Christopher A Eide; Joshua J Lara; Christian Barreto-Vargas; Luis F Jave-Suarez; Georgios Nteliopoulos; Alistair G Reid; Dragana Milojkovic; Brian J Druker; Jane Apperley; Jamshid S Khorashad; Anna M Eiring Journal: Oncogene Date: 2021-03-12 Impact factor: 9.867
Authors: Jan Styczyński; Lidia Gil; Krzysztof Czyżewski; Beata Kołodziej; Beata Kuryło-Rafińska; Krzysztof Lewandowski; Michał Gniot; Maria Lewandowska; Mieczysław Komarnicki; Mariusz Wysocki Journal: Contemp Oncol (Pozn) Date: 2012-07-06
Authors: L J Crawford; E T Chan; M Aujay; T L Holyoake; J V Melo; H G Jorgensen; S Suresh; B Walker; A E Irvine Journal: Oncogenesis Date: 2014-03-03 Impact factor: 7.485